Impressive performance in an extraordinary year to date
Biopharma investments are up, led by large mezz deals
IPO valuations and proceeds are on record pace and post-IPO stock performance has been incredible.
Dx/Tools are on track for record investment, four IPOs boasted $1B+ market caps at mid-year
Led by many companies leveraging their technologies to aid the COVID-19 response.
HealthTech led post-IPO performance with a $2B+ IPO that then increased its stock price by over 100%
Companies focused on providing alternative care outside the hospital raised 46% of capital in this sector.